Trial Profile
A randomized phase II chemoprevention study of iloprost versus placebo in patients at high risk for lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Iloprost (Primary)
- Indications Bronchopulmonary dysplasia; Lung cancer
- Focus Therapeutic Use
- 05 Apr 2011 Results presented at the 102nd Annual Meeting of the American Association for Cancer Research.
- 22 Dec 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 04 Aug 2009 Results were presented at the 13th World Conference on Lung Cancer 2009.